2nd Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

10 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Oppose proposals to reduce data exclusivity.

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Defense DEF

Oppose domestic manufacturing/procurement mandates in NDAA for pharmaceutical products, APIs, & medical devices

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE

Medical/Disease Research/Clinical Labs MED

Support NIH research funding. Support implementation of 21st Century Cures Act.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Small Business SMB

Support changes to SBA's "affiliation rule." Support changes to Main Street Lending Program's eligibility criteria.

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Disaster Planning/Emergencies DIS

Support exemptions from California's COVID-19 stay-at-home order for the life sciences community

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Oppose "march-in" rights and "compulsory licensing" proposals. Support transferable exclusivity extensions to incentivize novel antibiotic Research and Development.

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support policy improvements to address antimicrobial resistance. Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices. Support improvements to the Strategic National Stockpile for pandemic testing preparedness. Support public education campaign on pandemic preparedness

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE

Medicare/Medicaid MMM

Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare. Support Ensuring Patient Access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, and legislation. Oppose drug importation proposals. Support temporary home administration of Medicare Part B infused and injectible medicines during the COVID-19 public health emergency. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance. Support separate reimbursement structure for novel antiobitoics to incentivize Research and Development. Support Medicare coverage of remote patient monitoring services.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, antimicrobial resistance, biodefense/pandemic, CDC, science/math education, and strategic stockpile funding and preparation; Coronavirus funding and response;FDA Appropriations; PTO Appropriations.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Support Research and Development and Net Operating Loss tax incentives

LobbyistCovered position, as disclosed
MOLLY FISHMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.